Microsampling Approach for Monitoring of Kinase Inhibitor Targeted Therapies (MISTIK)

Rennes University Hospital

Status: Enrolling

Conditions: Blood Concentrations of Nine Anti-cancer Drugs : Axitinib, Olaparib, regorafénib, Cabozantinib, Niraparib, Talazoparib, Palbociclib, Abemaciclib, Tucatinib

Treatments: Other: Measurement of drug concentrations

Study type: Observational

Funder types: Other

Identifiers

NCT05598788

35RC22_8962_MISTIK

Details and patient eligibility

About

The MISTIK project aims at clinically validating the technique of oral anticancer drugs determination by volumetric absorptive micro-sampling and at comparing the results to measurements performed on venous samples.

Full description

The International recommendations for the validation of DBS-based methods will be applied (Capiau et al, TDM, 2019) by including 40 patients per molecule of interest. Nine drugs will be monitored : axitinib, olaparib, regorafénib, cabozantinib, niraparib, talazoparib, palbociclib, abemaciclib, tucatinib.

Two samples will be collected from each patient, one by venous sampling and the second at the same time (approximately) using a capillary blood sample derived from a finger prick.

Enrollment: 360 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients treated with one of the 9 drugs concerned by the study : axitinib, olaparib, regorafénib, cabozantinib, niraparib, talazoparib, palbociclib, abemaciclib, tucatinib
• person who does not object to their participation in the research

Exclusion criteria

• Adults subject to legal protection (safeguard of justice, curatorship, guardianship), persons deprived of their liberty